Seelaus Asset Management LLC Sells 1,105 Shares of Hologic, Inc. (NASDAQ:HOLX)

Seelaus Asset Management LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 20.0% during the 4th quarter, Holdings Channel reports. The firm owned 4,430 shares of the medical equipment provider’s stock after selling 1,105 shares during the period. Seelaus Asset Management LLC’s holdings in Hologic were worth $319,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Benson Investment Management Company Inc. bought a new stake in shares of Hologic during the 4th quarter valued at $4,832,000. Clean Yield Group raised its position in shares of Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after purchasing an additional 7,266 shares during the period. Janus Henderson Group PLC raised its position in shares of Hologic by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Versor Investments LP bought a new stake in shares of Hologic during the 3rd quarter valued at $1,677,000. Finally, JPMorgan Chase & Co. raised its position in shares of Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after purchasing an additional 238,222 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 1.3 %

Shares of HOLX opened at $64.58 on Friday. Hologic, Inc. has a 1-year low of $63.88 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 3.03. The firm has a market capitalization of $14.58 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 2.14 and a beta of 0.97. The company has a 50-day moving average of $72.33 and a 200 day moving average of $77.76.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts expect that Hologic, Inc. will post 4.27 EPS for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.88% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

HOLX has been the subject of several research analyst reports. Morgan Stanley cut their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Stephens reaffirmed an “overweight” rating and set a $84.00 target price on shares of Hologic in a research note on Thursday. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Finally, Evercore ISI dropped their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.